Posts
- Get link
- X
- Other Apps
- Get link
- X
- Other Apps
- Get link
- X
- Other Apps
AACR 2023 | AEGEAN Trial: New Data on Neoadjuvant Chemotherapy/Immunotherapy + Adjuvant Immunotherapy Released
AACR 2023 | AEGEAN Trial: New Data on Neoadjuvant Chemotherapy/Immunotherapy + Adjuvant Immunotherapy Released
- Get link
- X
- Other Apps
SGBCC International Dialogue | Wang Jia & Professor William Gradishar: Controversies in Surgical Treatment for Stage IV Breast Cancer Patients at Initial Diagnosis
SGBCC International Dialogue | Wang Jia & Professor William Gradishar: Controversies in Surgical Treatment for Stage IV Breast Cancer Patients at Initial Diagnosis
- Get link
- X
- Other Apps
- Get link
- X
- Other Apps
WCLC 2023 | Dr. Harpole: Surgical outcomes from AEGEAN trial and subgroup analyses of patients who were EGFR-mutant
WCLC 2023 | Dr. Harpole: Surgical outcomes from AEGEAN trial and subgroup analyses of patients who were EGFR-mutant
- Get link
- X
- Other Apps
- Get link
- X
- Other Apps
- Get link
- X
- Other Apps
- Get link
- X
- Other Apps
- Get link
- X
- Other Apps
WCLC 2023 |Dr. Gainor reviews IMpower151: Is the high percentage of patients with EGFR mutations, the reason for the research’s failure ?
WCLC 2023 |Dr. Gainor reviews IMpower151: Is the high percentage of patients with EGFR mutations, the reason for the research’s failure ?
- Get link
- X
- Other Apps